Boc, Inc.

The Boc Group, Inc.

Linas V Kudzma

H Kenneth Spencer

Sherry A Severnak

Bor-Sheng Lin

Bao-Shan Huang

Ross C Terrell

Nhora L Lalinde

Kirsten H Deutsche

Compounds are disclosed of the formula ##STR1## where R.sup.2 is unsubstituted or substituted phenyl, R.sup.3 is lower alkyl, lower cycloalkyl or lower alkoxy lower alkyl, and L is selected from a wide variety of groups. This new class of compounds exhibit improved analgesic and anesthetic properties.

4-phenyl-4-N-(phenyl) amido piperidine derivatives and pharmaceutical

4-phenyl-4-[N-(phenyl)amido]piperidine compounds and pharmaceutical

4-Phenyl-4-(N-(phenyl)amido) piperidine derivatives and pharmaceutical

Compounds are disclosed of the formula ##STR1## wherein R.sup.1 is an unsubstituted or substituted herterocyclic ring system; R.sup.2 is an unsubstituted or substituted phenyl; R.sup.3 is a lower alkyl or lower alkoxy, and L is selected from a wide variety of groups.

4-heteropentacyclic-4-(N-(phenyl)amido) piperidine derivatives and

The present invention is directed to an improved stereoselective tandem substitution and reduction of an imine precursor to the cis form of 3-substituted-4-(phenylanilo)piperidine compounds or their substituted derivatives.

Stereoselective preparation of 3-substituted-4-piperidine compounds and

Compounds are disclosed of the formula ##STR1## where R.sup.1 is a six numbered heterocyclic ring; R.sup.2 is a substituted or unsubstituted phenyl; R.sup.3 is lower alkyl, and L is selected from a variety of groups.

4-heterohexacyclic-4-(N-(phenyl)amido) piperidine derivatives and

Compounds are disclosed of the formula ##STR1## where R.sup.1 is an unsubstituted or substituted heterocyclic ring system; R.sup.2 is an unsubstituted or substituted phenyl; R.sup.3 is a lower alkyl or lower alkoxy, and L is selected from a wide variety of groups.

4-heteropentacyclic-4-[N-(phenyl)amino] piperidine derivatives and

4-phenyl-4-(N-(phenyl)amido) piperidine derivatives and pharmaceutical

Compounds are disclosed of the formula ##STR1## optically active isomeric forms thereof, and/or pharmaceutically acceptable acid addition salts thereof, in which formula: R is defined in the disclosure.

Growing community of inventors

North Bergen, NJ, United States of America

Linas V Kudzma